Search

everythinglearnresearchcommunity

for

Search:↓

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

The conversation is about experiences with Indian medications for hair loss, specifically using Finax (finasteride), Minopep Gold (minoxidil), and Biotin Plus tablets. Users discuss side effects like low libido and hair regrowth results, with some switching to different brands or dosages to manage side effects.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

The user discusses their struggle with hair loss and inability to use Minoxidil or finasteride due to medical conditions. They are currently using Hairmetto gel and dermarolling, and are considering trying Breezula or Revivhair serum.

A user is using a topical spray containing Finasteride 1% and Minoxidil 5% along with other ingredients like glycerin and aqua, questioning if these are effective carrier agents. They apply it once daily and use a separate 5% Minoxidil solution at night.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The user is seeking advice on maximizing hair growth while using oral finasteride, topical minoxidil, Nizoral, and microneedling, and is considering adding a laser diode cap, topical finasteride, retinol, and caffeine. Suggestions include using tretinoin with minoxidil for better absorption, switching to dutasteride, and considering RU58841 or pyrilutamide.

A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The conversation discusses purchasing RU58841 for hair loss treatment, with recommendations for buying from Lyphar Biotech and Carolina Chemicals. It suggests storing RU58841 in the fridge.

Hair loss treatments, with users discussing their experiences with both RU58841 and Pyrilutamide, noting that the latter has only recently become available but may yield better results in the long term.

A product called HairMDL includes Minoxidil, Dutasteride, Latanoprost, caffeine, Tretinoin, and Triamcinolone. Users are curious about its effectiveness and safety, particularly regarding the topical steroid Triamcinolone.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

The conversation discusses how to use fluridil/topilutamide with other hair loss treatments like liquid minoxidil and CB-03-01, considering fluridil's hydrophobic nature and potential degradation with water. The user questions the necessity of washing hair only once per week as suggested by the manufacturer.

Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.

The user is exploring hair loss treatments and is interested in procyanidin B2 and annurca apples but has concerns about the effectiveness and availability of supplements. They cannot use Dutasteride or Finasteride and are considering Minoxidil with microneedling.

A woman with androgenic alopecia has been using birth control, spironolactone, finasteride, and oral minoxidil for hair loss. She sought to change her medications to dutasteride and bicalutamide, but her new dermatologist refused to prescribe them for off-label use.

The conversation discusses the sourcing of Pyril by major retailers like Minoxidil Max, RU Direct, and Actifolic. It involves treatments such as Minoxidil, finasteride, and RU58841 for hair loss.

A user is seeking advice on the efficacy and side effects of homemade topical solutions for hair loss, specifically bicalutamide, estradiol, cyproterone acetate, and spironolactone, as they cannot access RU58841 or pyrilutamide.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Potential success with the hair loss treatment Pyrilutamide, and possible group buying opportunities for it along with other treatments such as Finasteride and Minoxidil.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

A user is considering using topical finasteride, topical minoxidil, RU58841, and dermarolling twice a week to address hair loss after experiencing side effects with oral finasteride. They previously saw positive results with a topical spray containing finasteride, minoxidil, and tretinoin but discontinued use due to laziness.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.